Technical Data Sheet

InVivoSIM bispecific anti-human CD3 x BCMA (Teclistamab Biosimilar)

Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at https://bioxcell.com/terms-and-conditions.

Lot Specific Information

Lot Number: **Lot Specific***
Volume: **Lot Specific***
Concentration: **Lot Specific* (generally 4 to 11 mg/ml) ***
Total Protein: **Lot Specific***

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number:	**SIM0067**
Clone:	**Teclistamab**
Isotype:	Human IgG4, λ
Recommended Dilution Buffer:	InVivoPure pH 7.0 Dilution Buffer
Mutations:	S228P/F234A/L235A
Immunogen:	Human BCMA-Fc recombinant protein
Reported Applications:	Functional assays Flow cytometry ELISA Immunohistochemistry
Formulation:	PBS, pH 7.0 Contains no stabilizers or preservatives
Endotoxin:	≤0.5EU/mg (≤0.0005EU/µg) Determined by LAL gel clotting assay
Purity:	≥95% Determined by SDS-PAGE
Sterility:	0.2 µm filtration
Production:	Purified from cell culture supernatant in an animal-free facility
Purification:	Protein A
RRID:	
Molecular Weight:	150 kDa

Murine Pathogen Test Results

Mouse Norovirus: Negative, Mouse Parvovirus: Negative, Mouse Minute Virus: Negative, Mouse Hepatitis Virus: Negative, Reovirus Screen: Negative, Lymphocytic Choriomeningitis virus: Negative, Lactate Dehydrogenase-Elevating Virus: Negative, Mouse Rotavirus: Negative, Theiler's Murine Encephalomyelitis: Negative, Ectromelia/Mousepox Virus: Negative, Hantavirus: Negative, Polyoma Virus: Negative, Mouse Adenovirus: Negative, Sendai Virus: Negative, Mycoplasma Pulmonis: Negative, Pneumonia Virus of Mice: Negative, Mouse Cytomegalovirus: Negative, K Virus: Negative

Description

This non-therapeutic biosimilar antibody utilizes the same variable regions as the therapeutic antibody Teclistamab, making it ideal for research use. Teclistamab is a humanized IgG4 bispecific monoclonal antibody that targets both B-cell maturation antigen (BCMA) on malignant plasma cells and CD3ε on T cells. BCMA is predominantly expressed on plasma cells and plays a crucial role in their survival and proliferation. By simultaneously binding to BCMA and CD3, Teclistamab redirects T cells to recognize and eliminate BCMA-expressing multiple myeloma cells through T-cell activation and subsequent cytotoxicity. The Fc region of Teclistamab contains S228P/L234A/L235A mutations to minimize its immunological effector functions. This biosimilar antibody is a valuable tool for studying T-cell engagement, bispecific antibody mechanisms, and

BCMA-targeted therapies.

Storage

Store at the stock concentration at 4°C . **Do not freeze.**
It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at https://bioxcell.com/faqs.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

For a complete list of references, visit https://bioxcell.com/sim0067?bxcs=9k1b3a#tab_references or scan the QR code below.

Bio X Cell, LLC
https://bioxcell.com
+1-866-787-3444
customerservice@bioxcell.com

Conditions: For research use only. Not for use in diagnostic or therapeutic procedures.
Not for resale.
Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © 2025 Bio X Cell, LLC